Personalized mRNA cancer vaccine plus pembrolizumab cuts melanoma recurrence or death risk by 42% in Phase 3

Phase III results showed that adding a personalized mRNA-based cancer vaccine to pembrolizumab after surgery for high-risk melanoma reduced recurrence or death risk by 42% compared with pembrolizumab alone.

Detected & updated continuously · Source: Nebula